An update on laboratory assessment for direct oral anticoagulants (DOACs)

Robert C Gosselin, Dorothy M Adcock, Jonathan Douxfils

Résultats de recherche: Contribution à un journal/une revueArticle de revue

Résumé

The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti-Xa inhibitors, have been approved, including rivaroxaban, apixaban, edoxaban and betrixaban. Our knowledge about the effect of DOACs on laboratory testing, as well as the use of the laboratory for measuring DOACs has been an evolving process. These drugs are not routinely monitored in the same fashion as coumadin, but there is an increasing demand on the laboratory to have the capacity to adequately assess DOAC anticoagulant effect (pharmacodynamics) or levels (pharmacokinetics) in either emergent or the routine situations. This manuscript provides an update on laboratory guidance and progress of methods for measuring DOACs.

langue originaleAnglais
Pages (de - à)33-39
Nombre de pages7
journalInternational Journal of Laboratory Hematology
Volume41
Numéro de publicationS1
Les DOIs
étatPublié - 1 mai 2019

Empreinte digitale

Anticoagulants
Pharmacodynamics
Pharmacokinetics
Antithrombins
Warfarin
Testing
Pharmaceutical Preparations

Citer ceci

@article{32078f3ee1bf42f19314465fc99691aa,
title = "An update on laboratory assessment for direct oral anticoagulants (DOACs)",
abstract = "The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti-Xa inhibitors, have been approved, including rivaroxaban, apixaban, edoxaban and betrixaban. Our knowledge about the effect of DOACs on laboratory testing, as well as the use of the laboratory for measuring DOACs has been an evolving process. These drugs are not routinely monitored in the same fashion as coumadin, but there is an increasing demand on the laboratory to have the capacity to adequately assess DOAC anticoagulant effect (pharmacodynamics) or levels (pharmacokinetics) in either emergent or the routine situations. This manuscript provides an update on laboratory guidance and progress of methods for measuring DOACs.",
keywords = "direct oral anticoagulants, laboratory guidance, laboratory practice, laboratory testing",
author = "Gosselin, {Robert C} and Adcock, {Dorothy M} and Jonathan Douxfils",
note = "{\circledC} 2019 John Wiley & Sons Ltd.",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/ijlh.12992",
language = "English",
volume = "41",
pages = "33--39",
journal = "International Journal of Laboratory Hematology",
issn = "1751-553X",
publisher = "Wiley-Blackwell Publishing",
number = "S1",

}

An update on laboratory assessment for direct oral anticoagulants (DOACs). / Gosselin, Robert C; Adcock, Dorothy M; Douxfils, Jonathan.

Dans: International Journal of Laboratory Hematology, Vol 41, Numéro S1, 01.05.2019, p. 33-39.

Résultats de recherche: Contribution à un journal/une revueArticle de revue

TY - JOUR

T1 - An update on laboratory assessment for direct oral anticoagulants (DOACs)

AU - Gosselin, Robert C

AU - Adcock, Dorothy M

AU - Douxfils, Jonathan

N1 - © 2019 John Wiley & Sons Ltd.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti-Xa inhibitors, have been approved, including rivaroxaban, apixaban, edoxaban and betrixaban. Our knowledge about the effect of DOACs on laboratory testing, as well as the use of the laboratory for measuring DOACs has been an evolving process. These drugs are not routinely monitored in the same fashion as coumadin, but there is an increasing demand on the laboratory to have the capacity to adequately assess DOAC anticoagulant effect (pharmacodynamics) or levels (pharmacokinetics) in either emergent or the routine situations. This manuscript provides an update on laboratory guidance and progress of methods for measuring DOACs.

AB - The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti-Xa inhibitors, have been approved, including rivaroxaban, apixaban, edoxaban and betrixaban. Our knowledge about the effect of DOACs on laboratory testing, as well as the use of the laboratory for measuring DOACs has been an evolving process. These drugs are not routinely monitored in the same fashion as coumadin, but there is an increasing demand on the laboratory to have the capacity to adequately assess DOAC anticoagulant effect (pharmacodynamics) or levels (pharmacokinetics) in either emergent or the routine situations. This manuscript provides an update on laboratory guidance and progress of methods for measuring DOACs.

KW - direct oral anticoagulants

KW - laboratory guidance

KW - laboratory practice

KW - laboratory testing

UR - http://www.scopus.com/inward/record.url?scp=85065490404&partnerID=8YFLogxK

U2 - 10.1111/ijlh.12992

DO - 10.1111/ijlh.12992

M3 - Review article

C2 - 31069969

VL - 41

SP - 33

EP - 39

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

SN - 1751-553X

IS - S1

ER -